Global Radiation Injury Drugs Market

Radiation Injury Drugs Comprehensive Study by Type (Aerosurf, BMX-001, C-2E2, C-2E5, Des-Asp Angiotensin 1, DG-3, Others), Application (Solar and Cosmic Radiation, Man-Made Radiation (Computed Tomography, Cardiac Nuclear Medicine Scans, X-Ray), Others), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Diagnosis (Lymphocytes Count, Geiger-Muller Counter, Blood Test, Dosimeter) Players and Region - Global Market Outlook to 2026

Radiation Injury Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Radiation Injury Drugs Market Scope?
Radiation injury is defined as the damage to tissues from exposure to ionizing radiation. The ionizing radiation given in large doses can cause acute illness, which leads to a decrease in the production of blood cells and damages the GI tract. It also causes damage to the heart, blood vessels, brain, and especially the skin. The radiation injury can lead to decreased sperm and egg production in both men and women. The high prevalence of cancer patients worldwide and the decision to use radiation therapy are driving the growth of the market for drugs against radiation damage. For example, the International Agency for Research on Cancer reported that in 2020 there will be 19.3 million cancer cases worldwide and 10 million will have died from cancer. Therefore, an increase in cancer patients may fuel the growth of the radiation treatment drug market. Raising reimbursement policies related to radiation therapies and how to manage their side effects can fuel the growth of the radiation therapy drug market. However, a lack of patient awareness of the side effects of radiation therapy can hinder the growth of the radiation damage drug market. New radiation therapies to treat cancer with fewer side effects may hinder the growth of the radiation damage drug market.

The Radiation Injury Drugs market study is being classified by Type (Aerosurf, BMX-001, C-2E2, C-2E5, Des-Asp Angiotensin 1, DG-3 and Others), by Application (Solar and Cosmic Radiation, Man-Made Radiation [Computed Tomography, Cardiac Nuclear Medicine Scans, X-Ray] and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Radiation Injury Drugs market throughout the predicted period.

FirstString Research Inc. (United States), Pharmain Corp (United States), Synedgen Inc. (United States), Tonix Pharmaceuticals Holding Corp (United States), Windtree Therapeutics Inc. (United States), Merck Sharp & Dohme Corp. (Merck & Co., Inc.) (United States), AstraZeneca (United Kingdom), Pfizer, Inc. (United States), Novartis AG (Switzerland), Eli Lilly and Company (United States), F. Hoffmann-La Roche Ltd. (Switzerland) and Teva Pharmaceutical Industries Ltd. (Israel) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Radiation Injury Drugs market by Type, Application and Region.

On the basis of geography, the market of Radiation Injury Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Influencing Market Trend
  • Increase in Reimbursement Policies Related To the Radiation Therapies

Market Drivers
  • The High Prevalence of Cancer Patients Worldwide

Opportunities
  • Increased the Healthcare Expenditure

Restraints
  • New Radiation Therapies for the Treatment of Cancer with Less Side-Effect

Challenges
  • Lack of Awareness among the Patients Related To Side-Effects of Radiation


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Manufacturers of Radiation Injury Drugs, Suppliers and Distributors of Radiation Injury Drugs, Venture Capitalists and Private Equity Firms and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Type
  • Aerosurf
  • BMX-001
  • C-2E2
  • C-2E5
  • Des-Asp Angiotensin 1
  • DG-3
  • Others
By Application
  • Solar and Cosmic Radiation
  • Man-Made Radiation [Computed Tomography, Cardiac Nuclear Medicine Scans, X-Ray]
  • Others
By Route of Administration
  • Oral
  • Parenteral

By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By Diagnosis
  • Lymphocytes Count
  • Geiger-Muller Counter
  • Blood Test
  • Dosimeter

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The High Prevalence of Cancer Patients Worldwide
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness among the Patients Related To Side-Effects of Radiation
    • 3.4. Market Trends
      • 3.4.1. Increase in Reimbursement Policies Related To the Radiation Therapies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Radiation Injury Drugs, by Type, Application, Route of Administration, Distribution Channel, Diagnosis and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Radiation Injury Drugs (Value)
      • 5.2.1. Global Radiation Injury Drugs by: Type (Value)
        • 5.2.1.1. Aerosurf
        • 5.2.1.2. BMX-001
        • 5.2.1.3. C-2E2
        • 5.2.1.4. C-2E5
        • 5.2.1.5. Des-Asp Angiotensin 1
        • 5.2.1.6. DG-3
        • 5.2.1.7. Others
      • 5.2.2. Global Radiation Injury Drugs by: Application (Value)
        • 5.2.2.1. Solar and Cosmic Radiation
        • 5.2.2.2. Man-Made Radiation [Computed Tomography, Cardiac Nuclear Medicine Scans, X-Ray]
        • 5.2.2.3. Others
      • 5.2.3. Global Radiation Injury Drugs by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Parenteral
      • 5.2.4. Global Radiation Injury Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacy
        • 5.2.4.2. Online Pharmacy
        • 5.2.4.3. Retail Pharmacy
      • 5.2.5. Global Radiation Injury Drugs by: Diagnosis (Value)
        • 5.2.5.1. Lymphocytes Count
        • 5.2.5.2. Geiger-Muller Counter
        • 5.2.5.3. Blood Test
        • 5.2.5.4. Dosimeter
      • 5.2.6. Global Radiation Injury Drugs Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Radiation Injury Drugs (Volume)
      • 5.3.1. Global Radiation Injury Drugs by: Type (Volume)
        • 5.3.1.1. Aerosurf
        • 5.3.1.2. BMX-001
        • 5.3.1.3. C-2E2
        • 5.3.1.4. C-2E5
        • 5.3.1.5. Des-Asp Angiotensin 1
        • 5.3.1.6. DG-3
        • 5.3.1.7. Others
      • 5.3.2. Global Radiation Injury Drugs by: Application (Volume)
        • 5.3.2.1. Solar and Cosmic Radiation
        • 5.3.2.2. Man-Made Radiation [Computed Tomography, Cardiac Nuclear Medicine Scans, X-Ray]
        • 5.3.2.3. Others
      • 5.3.3. Global Radiation Injury Drugs by: Route of Administration (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Parenteral
      • 5.3.4. Global Radiation Injury Drugs by: Distribution Channel (Volume)
        • 5.3.4.1. Hospital Pharmacy
        • 5.3.4.2. Online Pharmacy
        • 5.3.4.3. Retail Pharmacy
      • 5.3.5. Global Radiation Injury Drugs by: Diagnosis (Volume)
        • 5.3.5.1. Lymphocytes Count
        • 5.3.5.2. Geiger-Muller Counter
        • 5.3.5.3. Blood Test
        • 5.3.5.4. Dosimeter
      • 5.3.6. Global Radiation Injury Drugs Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Radiation Injury Drugs (Price)
      • 5.4.1. Global Radiation Injury Drugs by: Type (Price)
  • 6. Radiation Injury Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. FirstString Research Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pharmain Corp (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Synedgen Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Tonix Pharmaceuticals Holding Corp (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Windtree Therapeutics Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck Sharp & Dohme Corp. (Merck & Co., Inc.) (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AstraZeneca (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eli Lilly and Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Radiation Injury Drugs Sale, by Type, Application, Route of Administration, Distribution Channel, Diagnosis and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Radiation Injury Drugs (Value)
      • 7.2.1. Global Radiation Injury Drugs by: Type (Value)
        • 7.2.1.1. Aerosurf
        • 7.2.1.2. BMX-001
        • 7.2.1.3. C-2E2
        • 7.2.1.4. C-2E5
        • 7.2.1.5. Des-Asp Angiotensin 1
        • 7.2.1.6. DG-3
        • 7.2.1.7. Others
      • 7.2.2. Global Radiation Injury Drugs by: Application (Value)
        • 7.2.2.1. Solar and Cosmic Radiation
        • 7.2.2.2. Man-Made Radiation [Computed Tomography, Cardiac Nuclear Medicine Scans, X-Ray]
        • 7.2.2.3. Others
      • 7.2.3. Global Radiation Injury Drugs by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Parenteral
      • 7.2.4. Global Radiation Injury Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacy
        • 7.2.4.2. Online Pharmacy
        • 7.2.4.3. Retail Pharmacy
      • 7.2.5. Global Radiation Injury Drugs by: Diagnosis (Value)
        • 7.2.5.1. Lymphocytes Count
        • 7.2.5.2. Geiger-Muller Counter
        • 7.2.5.3. Blood Test
        • 7.2.5.4. Dosimeter
      • 7.2.6. Global Radiation Injury Drugs Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Radiation Injury Drugs (Volume)
      • 7.3.1. Global Radiation Injury Drugs by: Type (Volume)
        • 7.3.1.1. Aerosurf
        • 7.3.1.2. BMX-001
        • 7.3.1.3. C-2E2
        • 7.3.1.4. C-2E5
        • 7.3.1.5. Des-Asp Angiotensin 1
        • 7.3.1.6. DG-3
        • 7.3.1.7. Others
      • 7.3.2. Global Radiation Injury Drugs by: Application (Volume)
        • 7.3.2.1. Solar and Cosmic Radiation
        • 7.3.2.2. Man-Made Radiation [Computed Tomography, Cardiac Nuclear Medicine Scans, X-Ray]
        • 7.3.2.3. Others
      • 7.3.3. Global Radiation Injury Drugs by: Route of Administration (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Parenteral
      • 7.3.4. Global Radiation Injury Drugs by: Distribution Channel (Volume)
        • 7.3.4.1. Hospital Pharmacy
        • 7.3.4.2. Online Pharmacy
        • 7.3.4.3. Retail Pharmacy
      • 7.3.5. Global Radiation Injury Drugs by: Diagnosis (Volume)
        • 7.3.5.1. Lymphocytes Count
        • 7.3.5.2. Geiger-Muller Counter
        • 7.3.5.3. Blood Test
        • 7.3.5.4. Dosimeter
      • 7.3.6. Global Radiation Injury Drugs Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Radiation Injury Drugs (Price)
      • 7.4.1. Global Radiation Injury Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Radiation Injury Drugs: by Type(USD Million)
  • Table 2. Radiation Injury Drugs Aerosurf , by Region USD Million (2015-2020)
  • Table 3. Radiation Injury Drugs BMX-001 , by Region USD Million (2015-2020)
  • Table 4. Radiation Injury Drugs C-2E2 , by Region USD Million (2015-2020)
  • Table 5. Radiation Injury Drugs C-2E5 , by Region USD Million (2015-2020)
  • Table 6. Radiation Injury Drugs Des-Asp Angiotensin 1 , by Region USD Million (2015-2020)
  • Table 7. Radiation Injury Drugs DG-3 , by Region USD Million (2015-2020)
  • Table 8. Radiation Injury Drugs Others , by Region USD Million (2015-2020)
  • Table 9. Radiation Injury Drugs: by Application(USD Million)
  • Table 10. Radiation Injury Drugs Solar and Cosmic Radiation , by Region USD Million (2015-2020)
  • Table 11. Radiation Injury Drugs Man-Made Radiation [Computed Tomography, Cardiac Nuclear Medicine Scans, X-Ray] , by Region USD Million (2015-2020)
  • Table 12. Radiation Injury Drugs Others , by Region USD Million (2015-2020)
  • Table 13. Radiation Injury Drugs: by Route of Administration(USD Million)
  • Table 14. Radiation Injury Drugs Oral , by Region USD Million (2015-2020)
  • Table 15. Radiation Injury Drugs Parenteral , by Region USD Million (2015-2020)
  • Table 16. Radiation Injury Drugs: by Distribution Channel(USD Million)
  • Table 17. Radiation Injury Drugs Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 18. Radiation Injury Drugs Online Pharmacy , by Region USD Million (2015-2020)
  • Table 19. Radiation Injury Drugs Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 20. Radiation Injury Drugs: by Diagnosis(USD Million)
  • Table 21. Radiation Injury Drugs Lymphocytes Count , by Region USD Million (2015-2020)
  • Table 22. Radiation Injury Drugs Geiger-Muller Counter , by Region USD Million (2015-2020)
  • Table 23. Radiation Injury Drugs Blood Test , by Region USD Million (2015-2020)
  • Table 24. Radiation Injury Drugs Dosimeter , by Region USD Million (2015-2020)
  • Table 25. South America Radiation Injury Drugs, by Country USD Million (2015-2020)
  • Table 26. South America Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 27. South America Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 28. South America Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 29. South America Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 30. South America Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 31. Brazil Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 32. Brazil Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 33. Brazil Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 34. Brazil Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 35. Brazil Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 36. Argentina Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 37. Argentina Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 38. Argentina Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 39. Argentina Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 40. Argentina Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 41. Rest of South America Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 42. Rest of South America Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 43. Rest of South America Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 44. Rest of South America Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 45. Rest of South America Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 46. Asia Pacific Radiation Injury Drugs, by Country USD Million (2015-2020)
  • Table 47. Asia Pacific Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 48. Asia Pacific Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 49. Asia Pacific Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 50. Asia Pacific Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 51. Asia Pacific Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 52. China Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 53. China Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 54. China Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 55. China Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 56. China Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 57. Japan Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 58. Japan Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 59. Japan Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 60. Japan Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 61. Japan Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 62. India Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 63. India Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 64. India Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 65. India Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 66. India Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 67. South Korea Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 68. South Korea Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 69. South Korea Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 70. South Korea Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 71. South Korea Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 72. Taiwan Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 73. Taiwan Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 74. Taiwan Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 75. Taiwan Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 76. Taiwan Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 77. Australia Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 78. Australia Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 79. Australia Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 80. Australia Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 81. Australia Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 83. Rest of Asia-Pacific Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 84. Rest of Asia-Pacific Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 85. Rest of Asia-Pacific Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 86. Rest of Asia-Pacific Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 87. Europe Radiation Injury Drugs, by Country USD Million (2015-2020)
  • Table 88. Europe Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 89. Europe Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 90. Europe Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 91. Europe Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 92. Europe Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 93. Germany Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 94. Germany Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 95. Germany Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 96. Germany Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 97. Germany Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 98. France Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 99. France Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 100. France Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 101. France Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 102. France Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 103. Italy Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 104. Italy Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 105. Italy Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 106. Italy Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 107. Italy Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 108. United Kingdom Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 109. United Kingdom Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 110. United Kingdom Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 111. United Kingdom Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 112. United Kingdom Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 113. Netherlands Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 114. Netherlands Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 115. Netherlands Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 116. Netherlands Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 117. Netherlands Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 118. Rest of Europe Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 119. Rest of Europe Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 120. Rest of Europe Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 121. Rest of Europe Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 122. Rest of Europe Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 123. MEA Radiation Injury Drugs, by Country USD Million (2015-2020)
  • Table 124. MEA Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 125. MEA Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 126. MEA Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 127. MEA Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 128. MEA Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 129. Middle East Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 130. Middle East Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 131. Middle East Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 132. Middle East Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 133. Middle East Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 134. Africa Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 135. Africa Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 136. Africa Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 137. Africa Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 138. Africa Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 139. North America Radiation Injury Drugs, by Country USD Million (2015-2020)
  • Table 140. North America Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 141. North America Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 142. North America Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 143. North America Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 144. North America Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 145. United States Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 146. United States Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 147. United States Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 148. United States Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 149. United States Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 150. Canada Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 151. Canada Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 152. Canada Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 153. Canada Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 154. Canada Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 155. Mexico Radiation Injury Drugs, by Type USD Million (2015-2020)
  • Table 156. Mexico Radiation Injury Drugs, by Application USD Million (2015-2020)
  • Table 157. Mexico Radiation Injury Drugs, by Route of Administration USD Million (2015-2020)
  • Table 158. Mexico Radiation Injury Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 159. Mexico Radiation Injury Drugs, by Diagnosis USD Million (2015-2020)
  • Table 160. Radiation Injury Drugs Sales: by Type(K Tons)
  • Table 161. Radiation Injury Drugs Sales Aerosurf , by Region K Tons (2015-2020)
  • Table 162. Radiation Injury Drugs Sales BMX-001 , by Region K Tons (2015-2020)
  • Table 163. Radiation Injury Drugs Sales C-2E2 , by Region K Tons (2015-2020)
  • Table 164. Radiation Injury Drugs Sales C-2E5 , by Region K Tons (2015-2020)
  • Table 165. Radiation Injury Drugs Sales Des-Asp Angiotensin 1 , by Region K Tons (2015-2020)
  • Table 166. Radiation Injury Drugs Sales DG-3 , by Region K Tons (2015-2020)
  • Table 167. Radiation Injury Drugs Sales Others , by Region K Tons (2015-2020)
  • Table 168. Radiation Injury Drugs Sales: by Application(K Tons)
  • Table 169. Radiation Injury Drugs Sales Solar and Cosmic Radiation , by Region K Tons (2015-2020)
  • Table 170. Radiation Injury Drugs Sales Man-Made Radiation [Computed Tomography, Cardiac Nuclear Medicine Scans, X-Ray] , by Region K Tons (2015-2020)
  • Table 171. Radiation Injury Drugs Sales Others , by Region K Tons (2015-2020)
  • Table 172. Radiation Injury Drugs Sales: by Route of Administration(K Tons)
  • Table 173. Radiation Injury Drugs Sales Oral , by Region K Tons (2015-2020)
  • Table 174. Radiation Injury Drugs Sales Parenteral , by Region K Tons (2015-2020)
  • Table 175. Radiation Injury Drugs Sales: by Distribution Channel(K Tons)
  • Table 176. Radiation Injury Drugs Sales Hospital Pharmacy , by Region K Tons (2015-2020)
  • Table 177. Radiation Injury Drugs Sales Online Pharmacy , by Region K Tons (2015-2020)
  • Table 178. Radiation Injury Drugs Sales Retail Pharmacy , by Region K Tons (2015-2020)
  • Table 179. Radiation Injury Drugs Sales: by Diagnosis(K Tons)
  • Table 180. Radiation Injury Drugs Sales Lymphocytes Count , by Region K Tons (2015-2020)
  • Table 181. Radiation Injury Drugs Sales Geiger-Muller Counter , by Region K Tons (2015-2020)
  • Table 182. Radiation Injury Drugs Sales Blood Test , by Region K Tons (2015-2020)
  • Table 183. Radiation Injury Drugs Sales Dosimeter , by Region K Tons (2015-2020)
  • Table 184. South America Radiation Injury Drugs Sales, by Country K Tons (2015-2020)
  • Table 185. South America Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 186. South America Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 187. South America Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 188. South America Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 189. South America Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 190. Brazil Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 191. Brazil Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 192. Brazil Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 193. Brazil Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 194. Brazil Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 195. Argentina Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 196. Argentina Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 197. Argentina Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 198. Argentina Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 199. Argentina Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 200. Rest of South America Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 201. Rest of South America Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 202. Rest of South America Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 203. Rest of South America Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 204. Rest of South America Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 205. Asia Pacific Radiation Injury Drugs Sales, by Country K Tons (2015-2020)
  • Table 206. Asia Pacific Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 207. Asia Pacific Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 208. Asia Pacific Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 209. Asia Pacific Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 210. Asia Pacific Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 211. China Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 212. China Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 213. China Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 214. China Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 215. China Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 216. Japan Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 217. Japan Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 218. Japan Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 219. Japan Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 220. Japan Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 221. India Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 222. India Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 223. India Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 224. India Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 225. India Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 226. South Korea Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 227. South Korea Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 228. South Korea Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 229. South Korea Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 230. South Korea Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 231. Taiwan Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 232. Taiwan Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 233. Taiwan Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 234. Taiwan Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 235. Taiwan Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 236. Australia Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 237. Australia Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 238. Australia Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 239. Australia Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 240. Australia Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 241. Rest of Asia-Pacific Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 242. Rest of Asia-Pacific Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 243. Rest of Asia-Pacific Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 244. Rest of Asia-Pacific Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 245. Rest of Asia-Pacific Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 246. Europe Radiation Injury Drugs Sales, by Country K Tons (2015-2020)
  • Table 247. Europe Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 248. Europe Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 249. Europe Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 250. Europe Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 251. Europe Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 252. Germany Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 253. Germany Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 254. Germany Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 255. Germany Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 256. Germany Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 257. France Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 258. France Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 259. France Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 260. France Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 261. France Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 262. Italy Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 263. Italy Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 264. Italy Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 265. Italy Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 266. Italy Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 267. United Kingdom Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 268. United Kingdom Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 269. United Kingdom Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 270. United Kingdom Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 271. United Kingdom Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 272. Netherlands Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 273. Netherlands Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 274. Netherlands Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 275. Netherlands Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 276. Netherlands Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 277. Rest of Europe Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 278. Rest of Europe Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 279. Rest of Europe Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 280. Rest of Europe Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 281. Rest of Europe Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 282. MEA Radiation Injury Drugs Sales, by Country K Tons (2015-2020)
  • Table 283. MEA Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 284. MEA Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 285. MEA Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 286. MEA Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 287. MEA Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 288. Middle East Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 289. Middle East Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 290. Middle East Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 291. Middle East Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 292. Middle East Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 293. Africa Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 294. Africa Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 295. Africa Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 296. Africa Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 297. Africa Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 298. North America Radiation Injury Drugs Sales, by Country K Tons (2015-2020)
  • Table 299. North America Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 300. North America Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 301. North America Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 302. North America Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 303. North America Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 304. United States Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 305. United States Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 306. United States Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 307. United States Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 308. United States Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 309. Canada Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 310. Canada Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 311. Canada Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 312. Canada Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 313. Canada Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 314. Mexico Radiation Injury Drugs Sales, by Type K Tons (2015-2020)
  • Table 315. Mexico Radiation Injury Drugs Sales, by Application K Tons (2015-2020)
  • Table 316. Mexico Radiation Injury Drugs Sales, by Route of Administration K Tons (2015-2020)
  • Table 317. Mexico Radiation Injury Drugs Sales, by Distribution Channel K Tons (2015-2020)
  • Table 318. Mexico Radiation Injury Drugs Sales, by Diagnosis K Tons (2015-2020)
  • Table 319. Radiation Injury Drugs: by Type(USD/Units)
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Company Basic Information, Sales Area and Its Competitors
  • Table 328. Company Basic Information, Sales Area and Its Competitors
  • Table 329. Company Basic Information, Sales Area and Its Competitors
  • Table 330. Company Basic Information, Sales Area and Its Competitors
  • Table 331. Company Basic Information, Sales Area and Its Competitors
  • Table 332. Radiation Injury Drugs: by Type(USD Million)
  • Table 333. Radiation Injury Drugs Aerosurf , by Region USD Million (2021-2026)
  • Table 334. Radiation Injury Drugs BMX-001 , by Region USD Million (2021-2026)
  • Table 335. Radiation Injury Drugs C-2E2 , by Region USD Million (2021-2026)
  • Table 336. Radiation Injury Drugs C-2E5 , by Region USD Million (2021-2026)
  • Table 337. Radiation Injury Drugs Des-Asp Angiotensin 1 , by Region USD Million (2021-2026)
  • Table 338. Radiation Injury Drugs DG-3 , by Region USD Million (2021-2026)
  • Table 339. Radiation Injury Drugs Others , by Region USD Million (2021-2026)
  • Table 340. Radiation Injury Drugs: by Application(USD Million)
  • Table 341. Radiation Injury Drugs Solar and Cosmic Radiation , by Region USD Million (2021-2026)
  • Table 342. Radiation Injury Drugs Man-Made Radiation [Computed Tomography, Cardiac Nuclear Medicine Scans, X-Ray] , by Region USD Million (2021-2026)
  • Table 343. Radiation Injury Drugs Others , by Region USD Million (2021-2026)
  • Table 344. Radiation Injury Drugs: by Route of Administration(USD Million)
  • Table 345. Radiation Injury Drugs Oral , by Region USD Million (2021-2026)
  • Table 346. Radiation Injury Drugs Parenteral , by Region USD Million (2021-2026)
  • Table 347. Radiation Injury Drugs: by Distribution Channel(USD Million)
  • Table 348. Radiation Injury Drugs Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 349. Radiation Injury Drugs Online Pharmacy , by Region USD Million (2021-2026)
  • Table 350. Radiation Injury Drugs Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 351. Radiation Injury Drugs: by Diagnosis(USD Million)
  • Table 352. Radiation Injury Drugs Lymphocytes Count , by Region USD Million (2021-2026)
  • Table 353. Radiation Injury Drugs Geiger-Muller Counter , by Region USD Million (2021-2026)
  • Table 354. Radiation Injury Drugs Blood Test , by Region USD Million (2021-2026)
  • Table 355. Radiation Injury Drugs Dosimeter , by Region USD Million (2021-2026)
  • Table 356. South America Radiation Injury Drugs, by Country USD Million (2021-2026)
  • Table 357. South America Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 358. South America Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 359. South America Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 360. South America Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 361. South America Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 362. Brazil Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 363. Brazil Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 364. Brazil Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 365. Brazil Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 366. Brazil Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 367. Argentina Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 368. Argentina Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 369. Argentina Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 370. Argentina Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 371. Argentina Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 372. Rest of South America Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 373. Rest of South America Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 374. Rest of South America Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 375. Rest of South America Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 376. Rest of South America Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 377. Asia Pacific Radiation Injury Drugs, by Country USD Million (2021-2026)
  • Table 378. Asia Pacific Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 379. Asia Pacific Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 380. Asia Pacific Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 381. Asia Pacific Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 382. Asia Pacific Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 383. China Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 384. China Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 385. China Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 386. China Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 387. China Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 388. Japan Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 389. Japan Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 390. Japan Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 391. Japan Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 392. Japan Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 393. India Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 394. India Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 395. India Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 396. India Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 397. India Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 398. South Korea Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 399. South Korea Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 400. South Korea Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 401. South Korea Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 402. South Korea Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 403. Taiwan Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 404. Taiwan Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 405. Taiwan Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 406. Taiwan Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 407. Taiwan Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 408. Australia Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 409. Australia Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 410. Australia Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 411. Australia Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 412. Australia Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 413. Rest of Asia-Pacific Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 414. Rest of Asia-Pacific Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 415. Rest of Asia-Pacific Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 416. Rest of Asia-Pacific Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 417. Rest of Asia-Pacific Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 418. Europe Radiation Injury Drugs, by Country USD Million (2021-2026)
  • Table 419. Europe Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 420. Europe Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 421. Europe Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 422. Europe Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 423. Europe Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 424. Germany Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 425. Germany Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 426. Germany Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 427. Germany Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 428. Germany Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 429. France Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 430. France Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 431. France Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 432. France Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 433. France Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 434. Italy Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 435. Italy Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 436. Italy Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 437. Italy Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 438. Italy Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 439. United Kingdom Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 440. United Kingdom Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 441. United Kingdom Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 442. United Kingdom Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 443. United Kingdom Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 444. Netherlands Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 445. Netherlands Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 446. Netherlands Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 447. Netherlands Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 448. Netherlands Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 449. Rest of Europe Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 450. Rest of Europe Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 451. Rest of Europe Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 452. Rest of Europe Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 453. Rest of Europe Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 454. MEA Radiation Injury Drugs, by Country USD Million (2021-2026)
  • Table 455. MEA Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 456. MEA Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 457. MEA Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 458. MEA Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 459. MEA Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 460. Middle East Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 461. Middle East Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 462. Middle East Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 463. Middle East Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 464. Middle East Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 465. Africa Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 466. Africa Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 467. Africa Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 468. Africa Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 469. Africa Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 470. North America Radiation Injury Drugs, by Country USD Million (2021-2026)
  • Table 471. North America Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 472. North America Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 473. North America Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 474. North America Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 475. North America Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 476. United States Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 477. United States Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 478. United States Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 479. United States Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 480. United States Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 481. Canada Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 482. Canada Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 483. Canada Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 484. Canada Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 485. Canada Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 486. Mexico Radiation Injury Drugs, by Type USD Million (2021-2026)
  • Table 487. Mexico Radiation Injury Drugs, by Application USD Million (2021-2026)
  • Table 488. Mexico Radiation Injury Drugs, by Route of Administration USD Million (2021-2026)
  • Table 489. Mexico Radiation Injury Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 490. Mexico Radiation Injury Drugs, by Diagnosis USD Million (2021-2026)
  • Table 491. Radiation Injury Drugs Sales: by Type(K Tons)
  • Table 492. Radiation Injury Drugs Sales Aerosurf , by Region K Tons (2021-2026)
  • Table 493. Radiation Injury Drugs Sales BMX-001 , by Region K Tons (2021-2026)
  • Table 494. Radiation Injury Drugs Sales C-2E2 , by Region K Tons (2021-2026)
  • Table 495. Radiation Injury Drugs Sales C-2E5 , by Region K Tons (2021-2026)
  • Table 496. Radiation Injury Drugs Sales Des-Asp Angiotensin 1 , by Region K Tons (2021-2026)
  • Table 497. Radiation Injury Drugs Sales DG-3 , by Region K Tons (2021-2026)
  • Table 498. Radiation Injury Drugs Sales Others , by Region K Tons (2021-2026)
  • Table 499. Radiation Injury Drugs Sales: by Application(K Tons)
  • Table 500. Radiation Injury Drugs Sales Solar and Cosmic Radiation , by Region K Tons (2021-2026)
  • Table 501. Radiation Injury Drugs Sales Man-Made Radiation [Computed Tomography, Cardiac Nuclear Medicine Scans, X-Ray] , by Region K Tons (2021-2026)
  • Table 502. Radiation Injury Drugs Sales Others , by Region K Tons (2021-2026)
  • Table 503. Radiation Injury Drugs Sales: by Route of Administration(K Tons)
  • Table 504. Radiation Injury Drugs Sales Oral , by Region K Tons (2021-2026)
  • Table 505. Radiation Injury Drugs Sales Parenteral , by Region K Tons (2021-2026)
  • Table 506. Radiation Injury Drugs Sales: by Distribution Channel(K Tons)
  • Table 507. Radiation Injury Drugs Sales Hospital Pharmacy , by Region K Tons (2021-2026)
  • Table 508. Radiation Injury Drugs Sales Online Pharmacy , by Region K Tons (2021-2026)
  • Table 509. Radiation Injury Drugs Sales Retail Pharmacy , by Region K Tons (2021-2026)
  • Table 510. Radiation Injury Drugs Sales: by Diagnosis(K Tons)
  • Table 511. Radiation Injury Drugs Sales Lymphocytes Count , by Region K Tons (2021-2026)
  • Table 512. Radiation Injury Drugs Sales Geiger-Muller Counter , by Region K Tons (2021-2026)
  • Table 513. Radiation Injury Drugs Sales Blood Test , by Region K Tons (2021-2026)
  • Table 514. Radiation Injury Drugs Sales Dosimeter , by Region K Tons (2021-2026)
  • Table 515. South America Radiation Injury Drugs Sales, by Country K Tons (2021-2026)
  • Table 516. South America Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 517. South America Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 518. South America Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 519. South America Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 520. South America Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 521. Brazil Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 522. Brazil Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 523. Brazil Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 524. Brazil Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 525. Brazil Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 526. Argentina Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 527. Argentina Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 528. Argentina Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 529. Argentina Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 530. Argentina Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 531. Rest of South America Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 532. Rest of South America Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 533. Rest of South America Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 534. Rest of South America Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 535. Rest of South America Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 536. Asia Pacific Radiation Injury Drugs Sales, by Country K Tons (2021-2026)
  • Table 537. Asia Pacific Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 538. Asia Pacific Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 539. Asia Pacific Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 540. Asia Pacific Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 541. Asia Pacific Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 542. China Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 543. China Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 544. China Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 545. China Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 546. China Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 547. Japan Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 548. Japan Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 549. Japan Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 550. Japan Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 551. Japan Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 552. India Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 553. India Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 554. India Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 555. India Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 556. India Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 557. South Korea Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 558. South Korea Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 559. South Korea Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 560. South Korea Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 561. South Korea Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 562. Taiwan Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 563. Taiwan Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 564. Taiwan Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 565. Taiwan Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 566. Taiwan Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 567. Australia Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 568. Australia Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 569. Australia Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 570. Australia Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 571. Australia Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 572. Rest of Asia-Pacific Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 573. Rest of Asia-Pacific Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 574. Rest of Asia-Pacific Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 575. Rest of Asia-Pacific Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 576. Rest of Asia-Pacific Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 577. Europe Radiation Injury Drugs Sales, by Country K Tons (2021-2026)
  • Table 578. Europe Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 579. Europe Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 580. Europe Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 581. Europe Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 582. Europe Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 583. Germany Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 584. Germany Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 585. Germany Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 586. Germany Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 587. Germany Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 588. France Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 589. France Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 590. France Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 591. France Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 592. France Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 593. Italy Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 594. Italy Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 595. Italy Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 596. Italy Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 597. Italy Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 598. United Kingdom Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 599. United Kingdom Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 600. United Kingdom Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 601. United Kingdom Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 602. United Kingdom Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 603. Netherlands Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 604. Netherlands Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 605. Netherlands Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 606. Netherlands Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 607. Netherlands Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 608. Rest of Europe Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 609. Rest of Europe Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 610. Rest of Europe Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 611. Rest of Europe Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 612. Rest of Europe Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 613. MEA Radiation Injury Drugs Sales, by Country K Tons (2021-2026)
  • Table 614. MEA Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 615. MEA Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 616. MEA Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 617. MEA Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 618. MEA Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 619. Middle East Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 620. Middle East Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 621. Middle East Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 622. Middle East Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 623. Middle East Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 624. Africa Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 625. Africa Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 626. Africa Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 627. Africa Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 628. Africa Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 629. North America Radiation Injury Drugs Sales, by Country K Tons (2021-2026)
  • Table 630. North America Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 631. North America Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 632. North America Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 633. North America Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 634. North America Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 635. United States Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 636. United States Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 637. United States Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 638. United States Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 639. United States Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 640. Canada Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 641. Canada Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 642. Canada Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 643. Canada Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 644. Canada Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 645. Mexico Radiation Injury Drugs Sales, by Type K Tons (2021-2026)
  • Table 646. Mexico Radiation Injury Drugs Sales, by Application K Tons (2021-2026)
  • Table 647. Mexico Radiation Injury Drugs Sales, by Route of Administration K Tons (2021-2026)
  • Table 648. Mexico Radiation Injury Drugs Sales, by Distribution Channel K Tons (2021-2026)
  • Table 649. Mexico Radiation Injury Drugs Sales, by Diagnosis K Tons (2021-2026)
  • Table 650. Radiation Injury Drugs: by Type(USD/Units)
  • Table 651. Research Programs/Design for This Report
  • Table 652. Key Data Information from Secondary Sources
  • Table 653. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Radiation Injury Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Radiation Injury Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Radiation Injury Drugs: by Route of Administration USD Million (2015-2020)
  • Figure 7. Global Radiation Injury Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 8. Global Radiation Injury Drugs: by Diagnosis USD Million (2015-2020)
  • Figure 9. South America Radiation Injury Drugs Share (%), by Country
  • Figure 10. Asia Pacific Radiation Injury Drugs Share (%), by Country
  • Figure 11. Europe Radiation Injury Drugs Share (%), by Country
  • Figure 12. MEA Radiation Injury Drugs Share (%), by Country
  • Figure 13. North America Radiation Injury Drugs Share (%), by Country
  • Figure 14. Global Radiation Injury Drugs: by Type K Tons (2015-2020)
  • Figure 15. Global Radiation Injury Drugs: by Application K Tons (2015-2020)
  • Figure 16. Global Radiation Injury Drugs: by Route of Administration K Tons (2015-2020)
  • Figure 17. Global Radiation Injury Drugs: by Distribution Channel K Tons (2015-2020)
  • Figure 18. Global Radiation Injury Drugs: by Diagnosis K Tons (2015-2020)
  • Figure 19. South America Radiation Injury Drugs Share (%), by Country
  • Figure 20. Asia Pacific Radiation Injury Drugs Share (%), by Country
  • Figure 21. Europe Radiation Injury Drugs Share (%), by Country
  • Figure 22. MEA Radiation Injury Drugs Share (%), by Country
  • Figure 23. North America Radiation Injury Drugs Share (%), by Country
  • Figure 24. Global Radiation Injury Drugs: by Type USD/Units (2015-2020)
  • Figure 25. Global Radiation Injury Drugs share by Players 2020 (%)
  • Figure 26. Global Radiation Injury Drugs share by Players (Top 3) 2020(%)
  • Figure 27. Global Radiation Injury Drugs share by Players (Top 5) 2020(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. FirstString Research Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. FirstString Research Inc. (United States) Revenue: by Geography 2020
  • Figure 31. Pharmain Corp (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pharmain Corp (United States) Revenue: by Geography 2020
  • Figure 33. Synedgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Synedgen Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Tonix Pharmaceuticals Holding Corp (United States) Revenue, Net Income and Gross profit
  • Figure 36. Tonix Pharmaceuticals Holding Corp (United States) Revenue: by Geography 2020
  • Figure 37. Windtree Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Windtree Therapeutics Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Merck Sharp & Dohme Corp. (Merck & Co., Inc.) (United States) Revenue, Net Income and Gross profit
  • Figure 40. Merck Sharp & Dohme Corp. (Merck & Co., Inc.) (United States) Revenue: by Geography 2020
  • Figure 41. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 42. AstraZeneca (United Kingdom) Revenue: by Geography 2020
  • Figure 43. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 45. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 46. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 47. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 48. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 49. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 50. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 51. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 52. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 53. Global Radiation Injury Drugs: by Type USD Million (2021-2026)
  • Figure 54. Global Radiation Injury Drugs: by Application USD Million (2021-2026)
  • Figure 55. Global Radiation Injury Drugs: by Route of Administration USD Million (2021-2026)
  • Figure 56. Global Radiation Injury Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 57. Global Radiation Injury Drugs: by Diagnosis USD Million (2021-2026)
  • Figure 58. South America Radiation Injury Drugs Share (%), by Country
  • Figure 59. Asia Pacific Radiation Injury Drugs Share (%), by Country
  • Figure 60. Europe Radiation Injury Drugs Share (%), by Country
  • Figure 61. MEA Radiation Injury Drugs Share (%), by Country
  • Figure 62. North America Radiation Injury Drugs Share (%), by Country
  • Figure 63. Global Radiation Injury Drugs: by Type K Tons (2021-2026)
  • Figure 64. Global Radiation Injury Drugs: by Application K Tons (2021-2026)
  • Figure 65. Global Radiation Injury Drugs: by Route of Administration K Tons (2021-2026)
  • Figure 66. Global Radiation Injury Drugs: by Distribution Channel K Tons (2021-2026)
  • Figure 67. Global Radiation Injury Drugs: by Diagnosis K Tons (2021-2026)
  • Figure 68. South America Radiation Injury Drugs Share (%), by Country
  • Figure 69. Asia Pacific Radiation Injury Drugs Share (%), by Country
  • Figure 70. Europe Radiation Injury Drugs Share (%), by Country
  • Figure 71. MEA Radiation Injury Drugs Share (%), by Country
  • Figure 72. North America Radiation Injury Drugs Share (%), by Country
  • Figure 73. Global Radiation Injury Drugs: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • FirstString Research Inc. (United States)
  • Pharmain Corp (United States)
  • Synedgen Inc. (United States)
  • Tonix Pharmaceuticals Holding Corp (United States)
  • Windtree Therapeutics Inc. (United States)
  • Merck Sharp & Dohme Corp. (Merck & Co., Inc.) (United States)
  • AstraZeneca (United Kingdom)
  • Pfizer, Inc. (United States)
  • Novartis AG (Switzerland)
  • Eli Lilly and Company (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
Select User Access Type

Key Highlights of Report


May 2021 209 Pages 52 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Radiation Injury Drugs Market Quantitative research analysis
Global Radiation Injury Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Radiation Injury Drugs market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Radiation Injury Drugs market are FirstString Research Inc. (United States), Pharmain Corp (United States), Synedgen Inc. (United States), Tonix Pharmaceuticals Holding Corp (United States), Windtree Therapeutics Inc. (United States), Merck Sharp & Dohme Corp. (Merck & Co., Inc.) (United States), AstraZeneca (United Kingdom), Pfizer, Inc. (United States), Novartis AG (Switzerland), Eli Lilly and Company (United States), F. Hoffmann-La Roche Ltd. (Switzerland) and Teva Pharmaceutical Industries Ltd. (Israel), to name a few.
In this highly competitive & fast evolving Radiation Injury Drugs industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Radiation Injury Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Calcium Acetate Tablet Comprehensive Study by Sales Channel (Online, Offline), Packaging (Plastic Strip, Box, Small Bottle, Other), End User (Hospitals, Clinics, Dialysis Centres, Others) Players and...
$ 3500
Antibacterial Drug Resistance Comprehensive Study by Drugs (Antibiotics, Antifungals, Antivirals, Antimalarials, Anthelmintics, Others), Disease Type (Complicated Urinary Tract Infection (cUTI), Comp...
$ 3750
Pharma Excipients Comprehensive Study by Type (Organic Chemicals (Carbohyrates, Petrochemicals), Inorganic Chemicals (Calcium Phosphates, Calcium Carbonate, Calcium Sulfate, Halites, Metallic Oxides)...
$ 3650
Tocotrienol Comprehensive Study by Type (Alpha, Beta, Gamma, Delta), Application (Breast Cancer, Hypertrophic Scars, Fracture Healing, NAFLD, Familial Dysautonomia, Chronic Kidney Disease, Others), D...
$ 3650
Hemostatic Agents Comprehensive Study by Type (Passive Agents (Collagen, Cellulose, Gelatin, Polysaccharide hemospheres), Active Agents (Thrombin, FloSeal, Sealants), Newer Hemostatic Agents (Chitos...
$ 3750
Herbal Medicines Comprehensive Study by Type (Medicinal Part, Medicine Function, Active Ingredient), Application (Western Herbalism, Traditional Chinese Medicine, Others), Sales Channel (Online, Offl...
$ 3500